USA The Pharmaceutical Research and Manufacturers of America (PhRMA) has had a board reshake, naming Gilead Sciences Chairman and CEO Daniel O’Day as its new chair. The reorganisation comes after the industry group’s failed efforts to block the Inflation Reduction Act (IRA) and the departure of several high-profile members. Gilead…
Global Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million people were living with the disease globally in 2022. HIV treatments has become more manageable and are reaching more patients…
Global After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the company’s global commercial strategy and operations for HIV, COVID-19, and emerging viruses, she discusses the company’s strides in HIV prevention…
UAE Over the past few decades, the UAE has worked hard to attract top global talent to fill the gaps that its small local population was unable to. While the high salaries on offer were previously the main attractor to the country, with workers often staying for a couple of years…
Hong Kong Based at Gilead Sciences’ Hong Kong hub, as VP & GM of Asia, Turkey, and the Middle East, American Dustin Haines oversees a vast region that includes the “Asia 5” territories Singapore, Malaysia, Taiwan, Hong Kong and South Korea and is the biggest of the company’s intercontinental areas with respect…
UAE With a welter of regulatory upgrades in the UAE and Saudi Arabia in recent years, patients in the Middle East’s leading countries now have wider and faster access to cutting-edge biopharmaceutical innovation than ever before. Here, four leading lights in the region’s pharmaceutical industry highlight some of the most important…
UAE 16-year Gilead veteran, Vítor Papão, recently left Europe to take on a new role within the company as general manager of the vast Middle East & Russia cluster. He discusses the particularities of the region, and the partnerships and initiatives Gilead is actively pursuing with local stakeholders. We have…
UK A roundup of the latest UK healthcare, pharma and biotech news including AbbVie and Lilly’s departure from the country’s voluntary medicines pricing agreement, Moderna’s expanded footprint, UK biotech’s 2022 funding downturn and Gilead’s Yescarta approval from NICE. Northern Ireland Medicines supply still ‘problematic and inefficient’ (BBC News) According to…
Italy After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am] looking forward to joining the Angelini team and helping to chart the next chapter for [Angelini] Pharma. Jacopo Andreose Abrupt…
Vietnam A roundup of recent pharma and healthcare news from Vietnam including Gilead’s viral hepatitis initiative, the country’s explosion of dengue fever cases and the investigation into Boston Scientific’s Vietnam operations. Gilead initiative to improve viral hepatitis management in Vietnam and the Philippines (BioSpectrum Asia) Gilead Sciences has embarked on…
China A selection of the latest stories from Chinese pharma, including Novartis’ bet that the country will become its second biggest market by 2024 through the introduction of 50 new drugs, a new report by McKinsey that evaluates China’s impact on the global biopharma industry, AstraZeneca’s respiratory plans, and Gilead’s USD…
Global Gilead Sciences’ Jacopo Andreose PhD is a 20+ year pharma veteran and is today responsible for setting company strategy, planning and execution for over 150 countries across Asia, Russia/CIS, Latin and Central America, the Middle East, and Africa. In an exclusive conversation, Andreose outlines how Gilead was able to roll…
See our Cookie Privacy Policy Here